Docetaxel (Taxotere) - an update

Bibliography

• VERWEIJ J, CLAVEL M, CHEVALIER B: Paclitax el and do- cetaxel: not simply two of a kind. Ann. Oncol. (1994) 5:495–505.
   PubMed Web of Science ®Google Scholar
• CORTES JE, PAZDUR R: Docetaxel. J. Clin. Oncol. (1995) 13:2643–2655.
   PubMed Web of Science ®Google Scholar
• BISSETT D, SETANOIANS A, CASSIDY J eta].: Phase land pharmacokinetic study of Tax otere administered as a 24 hour infusion. Cancer Res. (1993) 53:523–527.
   Google Scholar
• BURRIS H, IRVIN R, KUHN J eta].: Phase I clinical trial of Tax otere administered as either a 2 hour or 6 hour in-travenous infusion. J Clin. Oncol. (1993) 11:950–958.
   Google Scholar
• EXTRA JM, ROUSSEAU F, BRUNO R et al.: Phase I andph ar macokinetic study of Tax otere given as a short in-travenous infusion. Cancer Res. (1993) 53:1037–1042.
   PubMed Web of Science ®Google Scholar
• PAZDUR R, NEWMAN RA, NEWMAN BM eta].: Phase I trialof Tax o tere: five-day schedule. J. Natl. Can Inst. (1992) 84:1781–1788.
   Google Scholar
• TOMIAK E, PICCART MJ, KERGER J eta].: Phase I study ofdocetaxel administered as a 1 hour intravenous infu-sion on a weekly basis. J Clin. Oncol. (1994) 12:1458–1467.
   Google Scholar
• FRANCIS PA, RIGAS JR, KRIS MG eta].: Phase II trial of do-cetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin. Oncol. (1994) 12:1232–1237.
   Google Scholar
• FOSSELLA FV, LEE JS, MURPHY WK eta].: Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J. Clin. Oncol. (1994) 12:1238–1244.
   Google Scholar
• MILLER VA, RIGAS JR, FRANCIS PA eta].: Phase II trial of a 75 mg/m2 dose of docetaxel with prednisone premedi-cation for patients with advanced non-small-cell lung cancer. Cancer (1995) 75:968–972.
   Google Scholar
• FOSSELLA FV, LEE JS, SHIN DM eta].: Phase II study of do-cetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. j Clin. Onca (1995) 13:645–651.
   Google Scholar
• GANDARA DR, VOKES E, GREEN M eta].: Docetaxel (Tax - o tere) in platinum-treated non-small-cell lung cancer (NSCLC): confirmation of prolonged survival in a multicenter trial. Proc. Am. Soc. Clin. Oncol. (1997) 16:454a. Abstract 1632.
   Google Scholar
• KUNITOH H, WATANABE K, ONOSHI T et al.: Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. j Clin. Oncol. (1996) 14:1649–1655.
   PubMed Web of Science ®Google Scholar
• SAARINEN A, JEKUNEN A, HALME M eta].: A Phase II trial of docetaxel in advanced non-small-cell lung cancer. Anti-Cancer Drugs (1996) 7:890–892.
   Google Scholar
• MILLWARD MJ, ZALCBERG J, BISCHOP JF et al.: Phase Itrial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. (1997) 15:750–758.
   PubMed Web of Science ®Google Scholar
• BERILLE J, LE CHEVALIER T, ZALCBERG JR: Overview onTax o ter e-Cisplatin (TXT-CDDP) combination in n o n - small-cell lung cancer (NSCLC). Ann. Oncol. (1996) 7 (Suppl. 5): 90. Abstract 427.
   Google Scholar
• ANDROULAKIS N, DIMOPOULOS AM, KOUROUSIS C: First-line treatment of advanced non-small-cell lung cancer (NSCLC) with docetaxel and cis-platin: a multi-center Phase II study. Proc. Am. Soc. Clin. Oncol. (1997) 16:461a. Abstract 1655.
   Google Scholar
• BELANI CP, BONOMI P, DOBBS T: Multicenter Phase IItrial of docetaxel and cisplatin combination in pa-tients with non-small-cell lung cancer. Proc. Am. Soc. Clin. Oncol. (1997) 16:462a. Abstract 1660.
   Google Scholar
• EARLY E, MILLER VA, GRANT SC eta].: Phase VII of doce-taxel and vinorelbine with filgrastim in patients with advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (1997) 16:467a. Abstract 1678.
   Google Scholar
• SCHILLER JH, LARSON M, PHARO L eta].: Phase I trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy. Proc. Am. Soc. Clin. On-col. (1997) 1 6:481a. Abstract 1733.
   Google Scholar
• WILLER C, EBERHARDT W, SERVE H eta].: Phase I clini-cal trial of docetaxel in combination with etoposide in patients with metastatic, non-pretreated non-small-cell lung cancer. Proc. Am. Soc. Clin. Oncol. (1997) 16:245a. Abstract 867.
   Google Scholar
• TAKEDA K, NEGORO S, MASUDA N eta].: Phase VII study of docetaxel and irinotecan in previously untreated advanced non-small-cell lung cancer. Proc. Am. Soc. Clin. Oncol. (1997) 16:484a. Abstract 1742.
   Google Scholar
• SEIDMAN AD, HUDIS CA: Phase II study evaluation of Tax otere as initial chemotherapy for metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. (1993) 12:63. Abstract
   Google Scholar
• CHEVALLIER B, FUMOLEAU P, KERBRAT P et al.: Doce-taxel is a major cytotoxic drug for the treatment of ad-vanced breast cancer: a Phase II trial of the clinical screening cooperative group of the EORTC. j Clin. On-col (1995) 13:314–322.
   PubMed Web of Science ®Google Scholar
• FUMOLEAU P, CHEVALLIER B, KERBRAT P eta].: A multi-center Phase II study of the efficacy and safety of doce-taxel as first-line treatment of advanced breast cancer: report of the clinical group of the EORTC. Ann. Oncol. (1996) 7:165–171.
   Google Scholar
• HUDIS CA, SEIDMAN AD, CROWN JP eta].: A Phase II and pharmacologic study of docetaxel as initial chemo-therapy for metastatic breast cancer. J. Clin. Oncol. (1996) 14:58–65.
   Google Scholar
• TRUDEAU ME, EISENHAUER EA, HIGGINS BP eta].: Doce-taxel in patients with metastatic breast cancer: a Phase II study of the National Cancer Institute of Canada clinical trials group. J. Clin. Oncol. (1996) 14:422–428.
   Google Scholar
• TEN BOKKEL HUININK WW, PROVE AM, PICCART M eta].: A Phase II trial of docetaxel (Tax otere) in second-line treatment with chemotherapy for advanced breast cancer. A study of the EORTC early clinical trials group. Ann. Oncol. (1994) 5:527–532.
   Google Scholar
• RAVDIN PM, BURRIS H, FIELDS SM et al.: Phase evalua-tion of Tax otere as chemotherapy for doxorubicin or mitoxantrone refractory metastatic breast cancer. Breast Cancer Res. Treat. (1994) 32:35. Abstract 27.
   Google Scholar
• VAN OOSTEROM AT, DIERAS V, TUBIANA-HULIN M eta].: Tax oter e in previously treated patients with metastatic breast carcinoma: stratification for anthracycline re-sistance. Proc. Am. Soc. Clin. Oncol. (1996) 15:141. Ab-stract 231.
   Google Scholar
• NABHOLTZ JM, MACKEY JR, SMYLIE M et al.: Phase II study of Tax otere, doxorubicin and cyclophospha-mide in the treatment of metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. (1997) 16:148a. Abstract 518.
   Google Scholar
• BOZEC I, NABHOLTZ JM, DIERAS V eta].: Docetaxel in combination with doxorubicin and with cyclophos-phamide as first-line chemotherapy in metastatic breast cancer: high activity and absence of cardiotox-icity. Proc. Am. Soc. Clin. Oncol. (1997) 16:163a. Abstract 566.
   Google Scholar
• ANTOINE EC, COEFFIC D, GOZY M eta].: A Phase II study of docetaxel and cisplatin in anthracycline pretreated metastatic breast cancer: preliminary results. Proc. Am. Soc. Clin. Oncol. (1997) 16:158a. Abstract 551.
   Google Scholar
• CHAN S, FRIEDRICHS K, NOEL D et al.: A randomized Phase III study of Tax otere versus doxorubicin in pa-tients with metastatic breast cancer who have failed an alkylating containing regimen: preliminary results. Proc. Am. Soc. Clin. Oncol. (1997) 16:154a. Abstract 540.
   Google Scholar
• NABHOLTZ JM, THUERLIMANN B, BEZWODA WR et al.: Tax o ter e (1) versusmitomycio C +vinblastine (MV) in patients with metastatic breast cancer who have failed an anthracycline containing regimen: preliminary re-sults of a randomized Phase III trial. Proc. Am. Soc. Clin. Oncol. (1997) 16:148a. Abstract 519.
   Google Scholar
• BONNETERRE J, ROCHE H, MONNIER A: Tax o ter e (TXT) versus 5-fluorouracil +navelbine (FUN) as second line chemotherapy in patients with metastatic breast can-cer (preliminary results). Proc. Am. Soc. Clin. Oncol. (1997) 16:162a. Abstract 564.
   Google Scholar
• BISHOP JF, DEWAR J, TATTERSALL MH eta].: Tax ol alone is equivalent to CMFP combination chemotherapy as frontline treatment in metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. (1997) 16:153a. Abstract 538.
   Google Scholar
• PARIDAENS R, BRUNING P, KLIJN J et al.: An EORTC crossover trial comparing single-agent Tax ol and doxorubicin as first and second line chemotherapy in advanced breast cancer. Proc. Am. Soc. Clin. Oncol (1997) 16:154a. Abstract 539.
   Google Scholar
• DREYFUSS Al, CLARK JR, NORRIS CM eta].: Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J. Clin. Oncol. (1996) 14:1672–1678.
   Google Scholar
• CATIMEL G, VERWEIJ J, MATTIJSSEN V et al.: Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann. Oncol. (1994) 5:533–537.
   PubMed Web of Science ®Google Scholar
• CHOUAKI N, COUTEAU C, LEYVRAZ S et al.: Phase II study of Tax otere in epidermoid carcinomas of the head and neck. Bull. Cancer (1996) 83:487-488. Abstract 155.
   Google Scholar
• EBIHARA S, FUJII H, SASAKI Y et al.: A late Phase II studyof docetax el in patients with head and neck cancer. Proc. Arm Soc. Clin. Oncol. (1997) 16:399a. Abstract 1425.
   Google Scholar
• POSNER M, NORRIS C, COLEVAS A eta].: Phase I/II trial ofdocetaxel, cisplatin, 5-fluorouracil and leucovorin for curable, locally advanced squamous cell cancer of the head and neck. Proc. Am. Soc. Clin. Oncol. (1997) 16:387a. Abstract 1380.
   Google Scholar
• SCHOFFSKI P, WANDERS J, CATIMEL G eta].: Apromisingregimen for treatment of the head and neck: docetax el and cisplatin. Ann. Oncol. (1996) 7 (Suppl. 5):79. Abstract 373P.
   Google Scholar
• VAN OOSTEROM AT: Docetaxel (Tax otere): a review of preclinical and clinical experience. Part II: clinical ex-perience. Anti-Cancer Drugs (1995) 6:358–368.
   Google Scholar
• WANDERS J, VAN OOSTEROM AT, GORE M et al.: Tax-otere toxicity-protective effects of premedication. Eur. J. Cancer (1993) 29A:5206.
   Google Scholar
• WANDERS J, SCHRIJVERS D, BRUNTSCH U et al.: The EORCT-ECTG experience with acute hypersensitivity reactions in Tax otere studies. Proc. Am. Soc. Clin. Oncol. (1993) 12:73. Abstract 94.
   Google Scholar